Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by Biofinanaceon Dec 09, 2020 3:32pm
381 Views
Post# 32069832

AGN has BEST KOLs from Fibrosis/Cough Universe

AGN has BEST KOLs from Fibrosis/Cough UniverseWhile we await for COVID NP120 interim data for 3rd week of Dec. I just want to highlight that AGN has been successful to include 2 of the best key opinion leaders of Fibrosis and Cough universe in its Scientific Advisory Board. 

1) Martin Kolb at McMaster - https://healthsci.mcmaster.ca/firh/physician-details/kolb-martin
He was Canada head for running both Nintadinib and Perfenidone Fibrosis trials and considered to be the best of the best. He is both active as Physician/Clinician and basic science reseacrch lab and always looking for new approaches for Idiopathic Lung Fibrosis (IPF). 
https://algernonpharmaceuticals.com/dr-martin-kolb/


2) Jacky Smith - https://www.research.manchester.ac.uk/portal/jacky.smith.html
Similar to Fibrosis, where the KOLs are very concentrated and are very few in nos, Cough space is also very much concentrated to few institutes. Jacky Smith has run all the Cough trials you can imagine in the past. She was Principle Investigator for both Bellus and Merck Cough studies. She was the inventor behind cough measurement system which patients put on during 12 weeks of cough trial. 
https://www.globenewswire.com/news-release/2020/02/07/1981672/0/en/Algernon-Pharmaceuticals-Appoints-Professor-of-Respiratory-Medicine-Dr-Jacky-Smith-to-Its-Medical-and-Scientific-Advisory-Board.html


I have had a chance to meet both in the past and are bright personalities. They wont easily associate their name with companies in which they dont believe. I guess its a testament on NP 120 relevance and legitamcy of AGN existence. 
<< Previous
Bullboard Posts
Next >>